{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T10:00:09Z","timestamp":1780999209977,"version":"3.54.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00259-026-07833-2","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:27:21Z","timestamp":1773707241000},"page":"4955-4967","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dual-tracer PET\/CT and cocktail therapy with [177Lu]Lu-FAP2286 and [177Lu]Lu-DOTATATE in G3 Neuroendocrine Tumors (NET)"],"prefix":"10.1007","volume":"53","author":[{"given":"Linwei","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyin","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingyan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingzhi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4088-7649","authenticated-orcid":false,"given":"Yue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"7833_CR1","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335\u201342. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0589.","journal-title":"JAMA Oncol"},{"key":"7833_CR2","doi-asserted-by":"publisher","first-page":"R153","DOI":"10.1530\/ERC-13-0125","volume":"21","author":"M Fraenkel","year":"2014","unstructured":"Fraenkel M, Kim M, Faggiano A, de Herr WW, Valk GD, Knowledge NETwork. Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. Endocr Relat Cancer. 2014;21:R153-63. https:\/\/doi.org\/10.1530\/ERC-13-0125.","journal-title":"Endocr Relat Cancer"},{"key":"7833_CR3","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1080\/17446651.2023.2237593","volume":"18","author":"S Pathak","year":"2023","unstructured":"Pathak S, Starr JS, Halfdanarson T, Sonbol MB. Understanding the increasing incidence of neuroendocrine tumors. Expert Rev Endocrinol Metab. 2023;18:377\u201385. https:\/\/doi.org\/10.1080\/17446651.2023.2237593.","journal-title":"Expert Rev Endocrinol Metab"},{"key":"7833_CR4","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/his.13975","volume":"76","author":"ID Nagtegaal","year":"2020","unstructured":"Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76:182\u20138. https:\/\/doi.org\/10.1111\/his.13975.","journal-title":"Histopathology"},{"key":"7833_CR5","doi-asserted-by":"publisher","first-page":"R67","DOI":"10.1530\/ERC-19-0400","volume":"27","author":"H Sorbye","year":"2020","unstructured":"Sorbye H, Kong G, Grozinsky-Glasberg S. PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3). Endocr Relat Cancer. 2020;27:R67\u201377. https:\/\/doi.org\/10.1530\/ERC-19-0400.","journal-title":"Endocr Relat Cancer"},{"key":"7833_CR6","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1634\/theoncologist.2015-0476","volume":"21","author":"R Coriat","year":"2016","unstructured":"Coriat R, Walter T, Terris B, Couvelard A, Ruszniewski P. Gastroenteropancreatic well-differentiated grade 3 neuroendocrine tumors: review and position statement. Oncologist. 2016;21:1191\u20139. https:\/\/doi.org\/10.1634\/theoncologist.2015-0476.","journal-title":"Oncologist"},{"key":"7833_CR7","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1159\/000493318","volume":"108","author":"H Sorbye","year":"2019","unstructured":"Sorbye H, Baudin E, Borbath I, Caplin M, Chen J, Cwikla JB, et al. Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3). Neuroendocrinology. 2019;108:54\u201362. https:\/\/doi.org\/10.1159\/000493318.","journal-title":"Neuroendocrinology"},{"key":"7833_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1607427.","journal-title":"N Engl J Med"},{"key":"7833_CR9","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"S Singh","year":"2024","unstructured":"Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, et al. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high\u2011dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2\u20133, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024;403:2807\u201317. https:\/\/doi.org\/10.1016\/S0140-6736(24)00701-3.","journal-title":"Lancet"},{"key":"7833_CR10","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1097\/MNM.0000000000000874","volume":"39","author":"E Demirci","year":"2018","unstructured":"Demirci E, Kabasakal L, Toklu T, Ocak M, \u015eahin OE, Alan-Selcuk N, et al. 177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update. Nucl Med Commun. 2018;39:789\u201396. https:\/\/doi.org\/10.1097\/MNM.0000000000000874.","journal-title":"Nucl Med Commun"},{"key":"7833_CR11","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/onco.13686","volume":"26","author":"AJ Liu","year":"2021","unstructured":"Liu AJ, Ueberroth BE, McGarrah PW, Buckner Petty SA, Kendi AT, Starr J, et al. Treatment outcomes of well-differentiated high\u2010grade neuroendocrine tumors. Oncologist. 2021;26:383\u20138. https:\/\/doi.org\/10.1002\/onco.13686.","journal-title":"Oncologist"},{"key":"7833_CR12","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s00259-017-3821-2","volume":"45","author":"SP Thang","year":"2018","unstructured":"Thang SP, Lung MS, Kong G, Hofman MS, Callahan J, Michael M, et al. Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis. Eur J Nucl Med Mol Imaging. 2018;45:262\u201377. https:\/\/doi.org\/10.1007\/s00259-017-3821-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7833_CR13","doi-asserted-by":"publisher","first-page":"377","DOI":"10.2967\/jnumed.118.215848","volume":"60","author":"J Zhang","year":"2019","unstructured":"Zhang J, Kulkarni HR, Singh A, Niepsch K, M\u00fcller D, Baum RP. Peptide receptor radionuclide therapy in grade 3 neuroendocrine neoplasms: safety and survival analysis in 69 patients. J Nucl Med. 2019;60:377\u201385. https:\/\/doi.org\/10.2967\/jnumed.118.215848.","journal-title":"J Nucl Med"},{"key":"7833_CR14","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1530\/ERC-18-0424","volume":"26","author":"EA Carlsen","year":"2019","unstructured":"Carlsen EA, Fazio N, Granberg D, Grozinsky-Glasberg S, Ahmadzadehfar H, Grana CM, et al. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study. Endocr Relat Cancer. 2019;26:227\u201339. https:\/\/doi.org\/10.1530\/ERC-18-0424.","journal-title":"Endocr Relat Cancer"},{"key":"7833_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14235792","volume":"14","author":"MN Becx","year":"2022","unstructured":"Becx MN, Minczeles NS, Brabander T, de Herr WW, Nonnekens J, Hofland J. A clinical guide to peptide receptor radionuclide therapy with 177Lu-DOTATATE in neuroendocrine tumor patients. Cancers (Basel). 2022;14:5792. https:\/\/doi.org\/10.3390\/cancers14235792.","journal-title":"Cancers (Basel)"},{"key":"7833_CR16","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00259-024-06795-7","volume":"52","author":"SS Banihashemian","year":"2024","unstructured":"Banihashemian SS, Akbari ME, Pirayesh E, Divband G, Abolhosseini Shahrnoy A, Nami R, et al. Feasibility and therapeutic potential of [177Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma. Eur J Nucl Med Mol Imaging. 2024;52:237\u201346. https:\/\/doi.org\/10.1007\/s00259-024-06795-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7833_CR17","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1007\/s00259-024-06635-8","volume":"51","author":"SS Banihashemian","year":"2024","unstructured":"Banihashemian SS, Divband G, Pirayesh E, Nikkholgh B, Amini H, Shahrnoy AA, et al. [68Ga]Ga-FAP-2286, a novel promising theragnostic approach for PET\/CT imaging in patients with various type of metastatic cancers. Eur J Nucl Med Mol Imaging. 2024;51:1981\u20138. https:\/\/doi.org\/10.1007\/s00259-024-06635-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7833_CR18","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1007\/s00259-023-06144-0","volume":"50","author":"BM Priv\u00e9","year":"2023","unstructured":"Priv\u00e9 BM, Boussihmad MA, Timmermans B, van Gemert WA, Peters SMB, Derks YHW, et al. Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies. Eur J Nucl Med Mol Imaging. 2023;50:1906\u201318. https:\/\/doi.org\/10.1007\/s00259-023-06144-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7833_CR19","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1007\/s00259-022-05842-5","volume":"49","author":"D Zboralski","year":"2022","unstructured":"Zboralski D, Hoehne A, Bredenbeck A, Schumann A, Nguyen M, Schneider E, et al. Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy. Eur J Nucl Med Mol Imaging. 2022;49:3651\u201367. https:\/\/doi.org\/10.1007\/s00259-022-05842-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7833_CR20","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1007\/s00259-023-06272-7","volume":"50","author":"J Millul","year":"2023","unstructured":"Millul J, Koepke L, Haridas GR, Sparrer KMJ, Mansi R, Fani M. Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides. Eur J Nucl Med Mol Imaging. 2023;50:3050\u201361. https:\/\/doi.org\/10.1007\/s00259-023-06272-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7833_CR21","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2967\/jnumed.120.259192","volume":"63","author":"RP Baum","year":"2022","unstructured":"Baum RP, Schuchardt C, Singh A, Chantadisai M, Robiller FC, Zhang J, et al. Feasibility, biodistribution, and preliminary dosimetry in peptide-targeted radionuclide therapy of diverse adenocarcinomas using177 lu-FAP-2286: first-in-humans results. J Nucl Med. 2022;63:415\u201323. https:\/\/doi.org\/10.2967\/jnumed.120.259192.","journal-title":"J Nucl Med"},{"key":"7833_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2025.111195","volume":"213","author":"X Bai","year":"2025","unstructured":"Bai X, Zhang N, Liu H, Xie Y, Gao B, Xu T, et al. A preliminary study on the safety and efficacy of 177Lu-FAP-2286 in gastrointestinal tumours with positive FAP expression. Radiother Oncol. 2025;213:111195. https:\/\/doi.org\/10.1016\/j.radonc.2025.111195.","journal-title":"Radiother Oncol"},{"key":"7833_CR23","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/RLU.0000000000005489","volume":"50","author":"L Li","year":"2025","unstructured":"Li L, Chen L, Zhang Y, Zhang Y, Chen Y. 177Lu-FAP-2286 therapy in a case of squamous lung cancer. Clin Nucl Med. 2025;50:103\u20134. https:\/\/doi.org\/10.1097\/RLU.0000000000005489.","journal-title":"Clin Nucl Med"},{"key":"7833_CR24","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1097\/RLU.0000000000004865","volume":"48","author":"L Li","year":"2023","unstructured":"Li L, Yang J, Peng D, Zhang Y, Chen Y. 177Lu-FAP-2286 therapy in a case of recurrent bladder cancer with multiple metastatic lesions. Clin Nucl Med. 2023;48:1012\u20134. https:\/\/doi.org\/10.1097\/RLU.0000000000004865.","journal-title":"Clin Nucl Med"},{"key":"7833_CR25","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1097\/RLU.0000000000005297","volume":"49","author":"Y Xie","year":"2024","unstructured":"Xie Y, Ma J, Tang W, Zhang Y, Zhang C, Chen Y. Efficacy and safety evaluation of 177Lu-FAP-2286 in the treatment of advanced lung cancer. Clin Nucl Med. 2024;49:830\u20137. https:\/\/doi.org\/10.1097\/RLU.0000000000005297.","journal-title":"Clin Nucl Med"},{"key":"7833_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-06048-5","author":"Z Rao","year":"2023","unstructured":"Rao Z, Zhang Y, Liu L, Wang M, Zhang C. [177Lu]Lu-FAP-2286 therapy in a case of right lung squamous cell carcinoma with systemic metastases. Eur J Nucl Med Mol Imaging. 2023. https:\/\/doi.org\/10.1007\/s00259-022-06048-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7833_CR27","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1097\/RLU.0000000000005169","volume":"49","author":"H Yang","year":"2024","unstructured":"Yang H, Liu H, Zhang Y, Zhang Y, Chen Y. Metastatic lung adenocarcinoma received combined 177Lu-FAP-2286 radiation therapy and targeted therapy. Clin Nucl Med. 2024;49:569\u201371. https:\/\/doi.org\/10.1097\/RLU.0000000000005169.","journal-title":"Clin Nucl Med"},{"key":"7833_CR28","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1097\/RLU.0000000000005255","volume":"49","author":"SS Banihashemian","year":"2024","unstructured":"Banihashemian SS, Bayat M, Pirayesh E, Divband G, Abolhosseini A, Akbari ME. First experience of radionuclide therapy with 177Lu-FAPI-2286 in a patient with metastatic mediastinal sarcoma. Clin Nucl Med. 2024;49:e334-7. https:\/\/doi.org\/10.1097\/RLU.0000000000005255.","journal-title":"Clin Nucl Med"},{"key":"7833_CR29","doi-asserted-by":"publisher","first-page":"4188","DOI":"10.1007\/s00259-024-06864-x","volume":"51","author":"S Kuyumcu","year":"2024","unstructured":"Kuyumcu S, Has-\u015eim\u015fek D. Evaluating the efficacy of [177Lu]Lu-FAP-2286 in combination therapy for metastatic breast cancer. Eur J Nucl Med Mol Imaging. 2024;51:4188\u20139. https:\/\/doi.org\/10.1007\/s00259-024-06864-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7833_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07258-3","author":"N Alan-Selcuk","year":"2025","unstructured":"Alan-Selcuk N, Akcay K, Beydagi G, Akyel R, Toklu T, Kabasakal L. [177Lu]Lu-FAP-2286 therapy in ovarian neuroendocrine carcinoma: a promising theranostic approach. Eur J Nucl Med Mol Imaging. 2025. https:\/\/doi.org\/10.1007\/s00259-025-07258-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7833_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/ph17121647","volume":"17","author":"H Liu","year":"2024","unstructured":"Liu H, Zhang X, Pan Y, Zhang J, Wen H, Zhang C, et al. Preclinical study of a dual-target molecular probe labeled with 68Ga targeting SSTR2 and FAP. Pharmaceuticals (Basel). 2024;17:1647. https:\/\/doi.org\/10.3390\/ph17121647.","journal-title":"Pharmaceuticals (Basel)"},{"key":"7833_CR32","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.2967\/jnumed.121.262992","volume":"63","author":"A Howe","year":"2022","unstructured":"Howe A, Bhatavdekar O, Salerno D, Josefsson A, Pacheco-Torres J, Bhujwalla ZM, et al. Combination of Carriers with Complementary Intratumoral Microdistributions of Delivered \u03b1 -Particles May Realize the Promise for225 Ac in Large, Solid Tumors. J Nucl Med. 2022;63:1223\u201330. https:\/\/doi.org\/10.2967\/jnumed.121.262992.","journal-title":"J Nucl Med"},{"key":"7833_CR33","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1007\/s00259-024-06710-0","volume":"51","author":"RR Nair","year":"2024","unstructured":"Nair RR, Prasad A, Bhatavdekar O, Sarkar A, Gabrielson KL, Sofou S. Combined, yet separate: cocktails of carriers (not drugs) for actinium-225 \u03b1-particle therapy of solid tumors expressing moderate-to-low levels of targetable markers. Eur J Nucl Med Mol Imaging. 2024;51:2649\u201362. https:\/\/doi.org\/10.1007\/s00259-024-06710-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7833_CR34","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.2967\/jnumed.124.268288","volume":"65","author":"K Michalski","year":"2024","unstructured":"Michalski K, Kosmala A, Hartrampf PE, Heinrich M, Serfling SE, Schl\u00f6telburg W, et al. [18F]FDG and [68Ga]Ga-FAPI-04\u2013directed imaging for outcome prediction in patients with high-grade neuroendocrine neoplasms. J Nucl Med. 2024;65:1899\u2013903. https:\/\/doi.org\/10.2967\/jnumed.124.268288.","journal-title":"J Nucl Med"},{"key":"7833_CR35","doi-asserted-by":"publisher","first-page":"3450","DOI":"10.1007\/s00259-024-06737-3","volume":"51","author":"S Xue","year":"2024","unstructured":"Xue S, Gafita A, Zhao Y, Mercolli L, Cheng F, Rauscher I, et al. Pre-therapy PET-based voxel-wise dosimetry prediction by characterizing intra-organ heterogeneity in PSMA-directed radiopharmaceutical theranostics. Eur J Nucl Med Mol Imaging. 2024;51:3450\u201360. https:\/\/doi.org\/10.1007\/s00259-024-06737-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7833_CR36","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1007\/s00259-023-06252-x","volume":"50","author":"A Akhavanallaf","year":"2023","unstructured":"Akhavanallaf A, Peterson AB, Fitzpatrick K, Roseland M, Wong KK, El-Naqa I, et al. The predictive value of pretherapy [68Ga]Ga-DOTA-TATE PET and biomarkers in [177Lu]Lu-PRRT tumor dosimetry. Eur J Nucl Med Mol Imaging. 2023;50:2984\u201396. https:\/\/doi.org\/10.1007\/s00259-023-06252-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7833_CR37","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1007\/s00259-017-3688-2","volume":"44","author":"M Del Prete","year":"2017","unstructured":"Del Prete M, Buteau F-A, Beauregard J-M. Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study. Eur J Nucl Med Mol Imaging. 2017;44:1490\u2013500. https:\/\/doi.org\/10.1007\/s00259-017-3688-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7833_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50969-8","volume":"15","author":"MC Riesco-Martinez","year":"2024","unstructured":"Riesco-Martinez MC, Capdevila J, Alonso V, Jimenez-Fonseca P, Teule A, Grande E, et al. Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 neuroendocrine neoplasms of gastroenteropancreatic or unknown origin: the multicenter phase 2 NICE-NEC trial (GETNE-T1913). Nat Commun. 2024;15:6753. https:\/\/doi.org\/10.1038\/s41467-024-50969-8.","journal-title":"Nat Commun"},{"key":"7833_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38611-5","volume":"14","author":"J Capdevila","year":"2023","unstructured":"Capdevila J, Hernando J, Teule A, Lopez C, Garcia-Carbonero R, Benavent M, et al. Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin. Nat Commun. 2023;14:2973. https:\/\/doi.org\/10.1038\/s41467-023-38611-5.","journal-title":"Nat Commun"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07833-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07833-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07833-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T09:24:09Z","timestamp":1780997049000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07833-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["7833"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07833-2","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"assertion":[{"value":"12 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the Affiliated Hospital of Southwest Medical University. All procedures involving human participants were performed in accordance with the ethical standards of the institutional committee, as well as the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any animal experiments. Written informed consents were obtained from the included subjects for participation in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors affirm that all human participants involved in this study have signed the consent form and agreed to the publication of their medical imaging.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}